Clinical Trial Update: Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating propranolol for neurocardiogenic syncope (fainting from sympathoadrenal imbalance) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurocardiogenic Syncope

Drugs mentioned

• Propranolol (propranolol)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Neurocardiogenic Syncope | Phase 4 | Status: COMPLETED